PLX-PAD

Phase 3Biologic

United Therapeutics

PLX-PAD is one of 145 biologic programs targeting Hip Fracture. It is currently in Phase 3.

Indications

Total Trials

Active Trials

144

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hip FractureActive, not recruiting

IschemiaActive, not recruiting

Pulmonary Arterial HypertensionActive, not recruiting

COVID-19Active, not recruiting

Hip FracturePhase 3

Active, not recruiting

IschemiaPhase 1

Active, not recruiting

Pulmonary Arterial HypertensionPhase 1

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

PLX-PAD

United Therapeutics

Phase 3

2 2

Spikevax

Moderna

Preclinical

21 3

Bnt162b2

BioNTech

Preclinical

29 4

COVID-19 Vaccine

Moderna

Preclinical

27 5

Biaxin

AbbVie

Preclinical

2 6

Stivarga

Bayer

Preclinical

1 7

Aimovig

Amgen

Preclinical

1 8

Aldactone

Pfizer

Preclinical

1 9

Nexavar

Bayer

Preclinical

1 10

Singulair

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ischemia5 trials

Expanded Access Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization

No longer available·PPluristem Ltd.··NCT03886506

Safety of Intramuscular Injection of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia

Completed·PPluristem Ltd.·Phase 1·NCT00919958·15 enrolled

Safety of Intramuscular Injections (IM) of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia (CLI)

Completed·PPluristem Ltd.·Phase 1·NCT00951210·12 enrolled

Show 2 more trials

Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization

Completed·PPluristem Ltd.·Phase 3·NCT03006770·213 enrolled

Expanded Access for Treatment Use of PLX-PAD in Critical Limb Ischemia (CLI)

Available·WWideTrial, Inc.··NCT03746899

COVID-192 trials

Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19

Terminated·PPluristem Ltd.·Phase 2·NCT04389450·66 enrolled

Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19

Terminated·PPluristem Ltd.·Phase 2·NCT04614025·23 enrolled

Intermittent Claudication1 trial

Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)

Completed·PPluristem Ltd.·Phase 2·NCT01679990·180 enrolled

Pulmonary Arterial Hypertension1 trial

Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)

Terminated· United Therapeutics logo

United Therapeutics·Phase 1·NCT01795950·6 enrolled

Hip Fracture1 trial

Treatment of Muscle Injury Following Arthroplasty for Hip Fracture (HF)

Completed·PPluristem Ltd.·Phase 3·NCT03451916·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for PLX-PAD. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PLX-PAD compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PLX-PAD. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — United Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: United Therapeutics

PLX-PAD

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ischemia5 trials

COVID-192 trials

Intermittent Claudication1 trial

Pulmonary Arterial Hypertension1 trial

Hip Fracture1 trial

References

Drug Info

Quick Facts

Related News